The U.S. CDC Advisory Committee on Immunization Practices (ACIP) on Friday urged for the pause on the Johnson & Johnson vaccine to be lifted and for administration to resume. It will be available to everyone ages 18 years and older.
“Lifting the pause is in the best public interest of the United States,” a participant in the advisory committee meeting said. Side effects of the vaccine will continue to be monitored and the CDC will continue to distribute information on the safety of the vaccine.
On April 13, the CDC and FDA had jointly recommended that the administration of the J&J vaccine be suspended until health officials had the opportunity to review whether the vaccine was in some way “related to or caused” a rare but severe type of blood clot with low platelets. 6 people, all women under the age of 50, had reported cases of blood clots up to two weeks after receiving the single dose vaccine.
At the time of the pause, there had been 7.5 million doses of the single shot vaccine administered in the U.S., according to the CDC.
The European Medicines Agency on Tuesday had said it found a “possible link” between the J&J vaccine and the rare blood clots and recommended a warning label be added to the vaccine, the Associated Press first reported.
During the review period, the CDC had recommended patients reschedule Covid-19 vaccine appointments to access the Pfizer- BioNTech or Moderna vaccines, neither of which has seen reports of blood clots with low platelets.